GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (FRA:1KA) » Definitions » Valuation Rank

GH Research (FRA:1KA) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is GH Research Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

GH Research Valuation Rank Related Terms

Thank you for viewing the detailed overview of GH Research's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

GH Research (FRA:1KA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (FRA:1KA) » Definitions » Valuation Rank
Comparable Companies
IMNM CDMO BMEA MRNS ORTX ALXO ORIC RNA ITOS URGN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
GHRS:USA
Address
28 Baggot Street Lower, Dublin, IRL, D02 NX43
Website
https://www.ghres.com
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. Its focus is on developing novel and proprietary 5-Methoxy-N,N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.